Viatris Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-09-24 EDT			5-day change	1st Jan Change
17.42 ^USD	+1.75%		+1.69%	+39.92%

09-23	Viatris Facing Multiple Paths to Earnings Growth, Oppenheimer Says	MT
09-23	Oppenheimer Initiates Viatris at Outperform With $25 Price Target	MT

Published on 03/25/2026 at 06:38 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Ladies and gentlemen, please welcome Head of Capital Markets Viatris, Bill Szablewski.

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

09-23	Viatris Facing Multiple Paths to Earnings Growth, Oppenheimer Says	MT
09-23	Oppenheimer Initiates Viatris at Outperform With $25 Price Target	MT
09-16	Gilead Sciences Expands Licensing Agreements for HIV Treatment	MT
09-16	Viatris Announces Approval Of WAKIX In Japan For Narcolepsy And Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome	CI
09-16	Viatris Says Wakix Wins Japan Approval for Narcolepsy, Obstructive Sleep Apnea	MT
09-16	Piper Sandler Adjusts Price Target on Viatris to $13 From $12, Keeps Neutral Rating	MT
09-10	Shell sells Rhode Island power plant to Constellation Energy for $715 million, acquires Hunlock Creek	RE
09-09	Leerink Partners Initiates Viatris at Outperform With $20 Price Target	MT
09-08	Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating	MT
09-08	Roivant's experimental lung disease drug meets goals in mid-stage study	RE
09-03	US FDA is working with manufacturers to boost estrogen patch supply amid access concerns	RE
08-28	Shield Therapeutics to Take Over US Commercialization of ACCRUFeR	MT
08-27	Shield Therapeutics takes full control of ferric maltol product in US	AN
08-25	Tialis shares slip on first-half revenue decline but loss narrows	AN
08-19	Viatris' China Policy Concerns Overstated, UBS Says	MT

Duration

Period

Sector